The effect of Aripiprazole augmentation of Sertraline in adolescents with obsessive-compulsive disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190104042227N1

Enrollment

Registered

2019-01-25

Start date

2018-08-01

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Administration of 50 to 150 mg sertraline daily for 12 weeks. Intervention 2: Intervention group: Administration of 50 to 150 mg of Sertraline daily and 5 to 10 mg

Eligibility

Sex/Gender

All

Age

12 Years to 19 Years

Inclusion criteria

Inclusion criteria: Obsessive-compulsive disorder adolescent patients

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Psychotic Psychiatric Disorders Mental retardation Substance abuse and alcohol abuse six months before the study began There is a physical condition that prevents the receiving of medications

Design outcomes

Primary

Measure	Time frame
The intensity of obsession - compulsion. Timepoint: At the time of arrival, the fourth, eighth and twelfth weeks. Method of measurement: Y-BOCS questionnaire.	—

Secondary

Measure	Time frame
The onset of side effects of drugs. Timepoint: Weeks zero, fourth, eighth and twelfth. Method of measurement: Clinical Examination and Interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Safaei

Kashan University of Medical Sciences

safaei-r@kaums.ac.ir+98 31 5554 9111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026